<DOC>
	<DOCNO>NCT00666783</DOCNO>
	<brief_summary>This clinical study design demonstrate single , intravenous dose palonosetron 0.25 mg inferior granisetron 3 mg prevent acute delay CINV also well tolerate Chinese cancer patient .</brief_summary>
	<brief_title>An Efficacy Safety Study Palonosetron Preventing Chemotherapy-Induced Nausea Vomiting ( CINV ) Chinese Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Male female , age range 18 yr 70 yr , histologically cytologically confirm malignant disease naive chemotherapy nonnaive interval least 14 day last one Karnofsky index 70 % anticipated survival time 90 day Scheduled receive follow cytotoxic agent base combination chemotherapy ( epirubicin 60 mg/m2 , cisplatin 75 mg/m2 ) study Day 1 chemotherapy accomplish study Day 1 No emetic episode antiemetic medication 24 hour precede chemotherapy administration Adequate organ function ( No impairment renal , hepatic , cardiac bone marrow function ) Use reliable contraceptive measure ( female childbearing potential ) negative pregnancy test baseline visit Provision write informed consent Inability understand cooperate study procedure Receipt investigational drug 30 day study entry Scheduled receive drug antiemetic efficacy 24 hr 5 day treatment Contraindications 5HT3 receptor antagonist Woman Patient Pregnancy lactation Diagnosed hypertension severe infectious disease Obstructive symptom gastrointestinal tract Symptomatic brain metastasis mental dysfunction Baseline QTc &gt; 500 m</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>